Apple’s iPhone Exports From India Double To Record $2.5B
-CNBC TV 18
https://www.cnbctv18.com/technology/apples-iphone-exports-from-india-double-torecord25billion-15617191.htm
Ipsen To Acquire Albireo For $42.00/Share Plus A Contingent Value Right Of $10.00/Share
Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial In The United States For The Treatment Of Individuals With Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.
IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023
IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).
Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023
Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023
Phathom Pharmaceuticals Announced Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic NERD; Both Vonoprazan 10 Mg And 20 Mg Doses Met Primary Endpoint
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced today positive topline results from PHALCON-NERD-301, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults in symptomatic non-erosive gastroesophageal reflux disease (sGERD or NERD).
Castle Biosciences Announced Preliminary FY 2022 Total Revenue Expected To Meet Or Exceed Top End Of Guided Range Of $132M–137M vs 135.47M Est
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022.
2022 total revenue expected to meet or exceed top end of guided range of $132–137 million
Esperion Sees Q4 Net Product Revenue $14.4M to $15.1M; FY Growth 38% to 40% YoY
Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2022 financial results and highlighted key upcoming anticipated milestones which represent continued execution of the Company's transformational plan.
Sage Therapeutics to Provide Update on 2023 Key Milestones at 41st Annual J.P. Morgan Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer, Barry Greene, will discuss the Company's progress in developing a leading brain health pipeline at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
CymaBay Therapeutics Announced Collaboration with Kaken Pharmaceutical to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis; Kaken to Make Upfront Payment To Cymabay Of ~$34M Plus Milestone Payments Up To ~$128.4M And Royal…
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis ("PBC").
Volition Issued Business Review 2022
VolitionRx Limited (NYSE AMERICAN: VNRX) has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations.
Volition's major achievements in 2022 include: